Management of Depressive Symptoms in Patient on Atomoxetine and Citalopram
The depressive symptoms are likely unrelated to the atomoxetine dose increase and should be managed by optimizing the citalopram or switching/augmenting the antidepressant regimen, not by adjusting atomoxetine. The atomoxetine dose escalation from 40 mg to 80 mg is appropriate per FDA labeling and should be maintained if ADHD symptoms are improving 1.
Critical Drug Interaction Consideration
First, verify whether the patient is on a strong CYP2D6 inhibitor or is a CYP2D6 poor metabolizer. Citalopram is NOT a strong CYP2D6 inhibitor, so the standard atomoxetine dosing applies 1. However, if the patient were on fluoxetine or paroxetine (which ARE strong CYP2D6 inhibitors), the atomoxetine dose should have been initiated at 40 mg/day and only increased to 80 mg/day after 4 weeks if symptoms failed to improve 1.
Addressing the Depressive Symptoms
Evidence on Atomoxetine for Depression
The evidence does NOT support atomoxetine as an effective treatment for depression:
- A randomized, double-blind, placebo-controlled trial found NO benefit when atomoxetine was added to sertraline for depression incompletely responsive to SSRI treatment (remission rates: 40.3% atomoxetine vs 37.8% placebo, p=0.865) 2
- A smaller open-label case series suggested possible benefit 3, but this is contradicted by the higher-quality controlled trial
- In Parkinson's disease patients, atomoxetine failed to improve depressive symptoms 4
Management Algorithm
Step 1: Assess the depression severity and treatment adequacy
- How long has the patient been on citalopram at the current dose?
- What is the current citalopram dose? (Maximum FDA-approved dose is 40 mg/day due to QT prolongation risk 5)
- Has the patient had adequate trial duration (typically 4-8 weeks at therapeutic dose)?
Step 2: Optimize or modify the antidepressant regimen
Based on American College of Physicians guidelines, the following strategies have moderate-certainty evidence for similar efficacy 6:
- Switch to another antidepressant (different class or same class)
- Augment with bupropion SR or buspirone (moderate-certainty evidence for similar efficacy to switching) 6
- Add cognitive behavioral therapy (moderate-certainty evidence for similar efficacy to antidepressants as first-line treatment) 6
Step 3: Do NOT reduce atomoxetine dose
The 80 mg/day atomoxetine dose is the standard target dose for adults and should be maintained if ADHD symptoms are responding 1. The FDA label explicitly states that after 2-4 additional weeks at 80 mg/day, the dose may be increased to a maximum of 100 mg if optimal response has not been achieved 1.
Important Caveats
Citalopram Dosing Safety
Be aware that citalopram doses >40 mg/day are associated with QT prolongation risk. A large Veterans Affairs study found that reducing citalopram from higher doses to ≤40 mg/day was associated with increased hospitalizations (adjusted HR=4.5), though this may reflect undertreated depression rather than direct harm from dose reduction 5.
Combination Safety
The combination of atomoxetine and citalopram has been studied and appears well-tolerated, though blood pressure and pulse should be monitored more closely than with monotherapy 7.
Screen for Bipolar Disorder
Before escalating any antidepressant treatment, screen for personal or family history of bipolar disorder, mania, or hypomania 1. Atomoxetine labeling specifically requires this screening prior to treatment initiation.
Monitor Suicidality
Atomoxetine carries a black box warning for increased suicidal ideation in children and adolescents with ADHD 1. While your patient's depressive symptoms may be unrelated to atomoxetine, increased monitoring is warranted when depression and atomoxetine treatment coexist.